April Salama

Positions:

Associate Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2004

University of North Carolina - Chapel Hill

Internal Medicine

The University of Chicago

Hematology/Oncology

The University of Chicago

Grants:

Collaborative Success: Expanding Options for Patients with Melanoma

Administered By
Duke Cancer Institute
Awarded By
National Institutes of Health
Role
Project Lead
Start Date
End Date

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.

Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Role
Principal Investigator
Start Date
End Date

INCB 24360-208 A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)

Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Role
Principal Investigator
Start Date
End Date

A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma

Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Role
Principal Investigator
Start Date
End Date

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator's Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma

Administered By
Duke Cancer Institute
Awarded By
Immunocore Limited
Role
Principal Investigator
Start Date
End Date

Publications:

Biomarkers in lung cancer: from early detection to novel therapeutics and decision making.

Lung cancer remains a significant cause of mortality worldwide. While advances in therapy continue to be made, the overall prognosis for patients diagnosed with lung cancer remains poor. Historically, markers such as age, performance status and disease stage have been used to risk-stratify patients and guide therapeutic decisions. These parameters provide some useful information, but more sensitive markers are clearly needed. Molecular and genetic studies have identified several such markers, which appear to play critical roles in carcinogenesis and affect patient outcomes. This article reviews a number of biomarkers that have been identified in lung cancer, and their prognostic and predictive roles.
Authors
Scott, A; Salgia, R
MLA Citation
Scott, April, and Ravi Salgia. “Biomarkers in lung cancer: from early detection to novel therapeutics and decision making.Biomarkers in Medicine, vol. 2, no. 6, Dec. 2008, pp. 577–86. Epmc, doi:10.2217/17520363.2.6.577.
URI
https://scholars.duke.edu/individual/pub1447608
PMID
19802373
Source
epmc
Published In
Biomarkers in Medicine
Volume
2
Published Date
Start Page
577
End Page
586
DOI
10.2217/17520363.2.6.577

A phase 1b/2 study of omaveloxolone in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma

Authors
Patel, SP; Hodi, FS; Gabrilovich, D; Chin, M; Gibney, G; Goldsberry, A; Gonzalez, R; Hurt, J; Markowitz, J; Whitman, E; Meyer, C; Salama, A
MLA Citation
Patel, S. P., et al. “A phase 1b/2 study of omaveloxolone in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma.” Annals of Oncology, vol. 28, 2017, p. xi30. Scopus, doi:10.1093/annonc/mdx760.
URI
https://scholars.duke.edu/individual/pub1315117
Source
scopus
Published In
Annals of Oncology
Volume
28
Published Date
Start Page
xi30
DOI
10.1093/annonc/mdx760

Characterizing Long-Term Outcomes in Metastatic Melanoma in 2020

Authors
Salama, A
URI
https://scholars.duke.edu/individual/pub1442436
Source
manual

Mind the gap: Gendered publication trends in oncology.

BACKGROUND:Investigating scientific publication trends in the field of oncology may highlight opportunities for improved representation, mentorship, collaboration, and advancement for women. METHODS:We conducted a bibliometric analysis of Annals of Surgical Oncology; Cancer; International Journal of Radiation Oncology, Biology, Physics (IJROBP); JAMA Oncology; and Journal of Clinical Oncology in 1990, 2000, 2010, and 2017. Full name and degree credentials per author role (ie, first or senior author), article type, publication year, and citation metrics were collected. First names were used to identify author gender. RESULTS:Across 9189 articles, female representation rose between 1990 and 2017 (first authors: 17.7% in 1990, 36.6% in 2017; senior authors: 11.7% in 1990, 28.5% in 2017). For the 50 most cited articles per year, women comprised a smaller percent of first (26.5%) and senior (19.9%) authors. The average citation count was higher for male first (44.8 per article) and senior (47.1) authors compared to female first (39.7) and senior (44.1) authors. With male senior authors, the first author was more likely male (71.4% male; 25.0% female); with female senior authors, first authors were 50.2% male and 47.6% female. IJROBP had the lowest total female representation among first (25.1%) and senior (16.7%) authors. Women had more MDs with Masters degrees, whereas men held more MDs only and more MDs with PhDs. CONCLUSION:Despite positive trends, substantial gendered differences in oncology publications persist. Fostering more women in oncology research will benefit female representation at many levels of academia and improve productivity, collaboration, and recruitment, especially in technical fields such as radiation and surgical oncology.
Authors
Dalal, NH; Chino, F; Williamson, H; Beasley, GM; Salama, AKS; Palta, M
MLA Citation
Dalal, Nicole H., et al. “Mind the gap: Gendered publication trends in oncology.Cancer, vol. 126, no. 12, June 2020, pp. 2859–65. Epmc, doi:10.1002/cncr.32818.
URI
https://scholars.duke.edu/individual/pub1435855
PMID
32212334
Source
epmc
Published In
Cancer
Volume
126
Published Date
Start Page
2859
End Page
2865
DOI
10.1002/cncr.32818

Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data.

Authors
Owonikoko, TK; Papadopoulos, KP; Gil-Martin, M; Moreno, V; Salama, AK; Calvo, E; Safran, H; González-Martín, A; Aljumaily, R; Mahadevan, D; Niu, J; Kal Mohan, K; Li, J; Stankevich, E; Mathias, M; Lowy, I; Fury, MG; Babiker, HM
MLA Citation
URI
https://scholars.duke.edu/individual/pub1434090
PMID
32137181
Source
pubmed
Published In
Ann Oncol
Volume
29 Suppl 8
Published Date
Start Page
viii461
End Page
viii462
DOI
10.1093/annonc/mdy289.048